Figure 7

TTK associates with aggressive subtypes and is a therapeutic target. (a) Kaplan–Meier survival curves are shown for Grade 3 tumors, lymph node-positive patients (LN⁺) and LN⁺ patients with grade 3 tumors. Log-rank Test and P-value were used for these survival curves. For patients with TNBC and HER2, survival was statistically significant using the Gehan–Breslow–Wilcoxon test (P-values marked by two asterisks), which gives more weight to deaths at early time points. The poorer survival of patients with high Ki67 tumors and high TTK staining was a trend, but it did not reach significance. Survival curves and statistical analyses were performed using GraphPad Prism. (b) TNBC and non-TNBC cell lines were treated for 6 days with the specified concentrations of docetaxel (doc) alone, TTK inhibitor (TTKi) alone or the combinations. The survival of cells was measured using the MTS/MTA assay, as described in Methods. ***P<0.001 comparing the combination with single agents and with non-TNBC cell lines from two-way ANOVA in GraphPad Prism. (c) MDA-MB-231 cells were treated with docetaxel or TTKi alone or in combination and collected at 96 h to perform apoptosis assays by flow cytometry. Early apoptotic cells were defined as annexin V+/7-AAD−. **P<0.01 and ***P<0.001 comparing treatments using one-way ANOVA in GraphPad Prism.